» Authors » L Maniscalco

L Maniscalco

Explore the profile of L Maniscalco including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 124
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Maniscalco L, Enea M, de Vries N, Mazzucco W, Boone A, Lavreysen O, et al.
Sci Rep . 2024 Jan; 14(1):2312. PMID: 38282043
The European healthcare sector faces a significant shortage of healthcare workers. Assessing the prevalence of this issue and understanding its direct and indirect determinants are essential for formulating effective recruitment...
2.
Di Fede O, Canepa F, Maniscalco L, Tozzo P, Matranga D, Giuliana G
BMC Oral Health . 2023 Jan; 23(1):4. PMID: 36597048
Introduction: Oral mucositis (OM) is a major side effect of cancer therapy, which is associated with significant symptoms, treatment delays and increased costs for the health system. It is an...
3.
Ali Hassan H, Banchi P, Chayaa R, Pascottini O, Maniscalco L, Iussich S, et al.
Theriogenology . 2022 Dec; 198:12-18. PMID: 36529107
To achieve optimal vitrification, tissue structure and fragment size represent a challenge for obtaining sufficient cooling velocity. Theoretically, thin ovarian tissue fragments lead to higher surface contact, hence higher solute...
4.
Gola C, Iussich S, Noury S, Martano M, Gattino F, Morello E, et al.
Vet J . 2020 Oct; 264:105538. PMID: 33012439
Cellular adaptation to a hypoxic microenvironment is essential for tumour progression and is largely mediated by HIF-1α and hypoxia-regulated factors, including CXCR4, VEGF-A and GLUT-1. In human osteosarcoma, hypoxia is...
5.
Massimini M, Palmieri C, De Maria R, Romanucci M, Malatesta D, De Martinis M, et al.
Vet Pathol . 2017 Apr; 54(3):405-412. PMID: 28438108
Canine osteosarcoma is highly resistant to current chemotherapy; thus, clarifying the mechanisms of tumor cell resistance to treatments is an urgent need. We tested the geldanamycin derivative 17-AAG (17-allylamino-17-demethoxygeldanamycin) prototype...
6.
Piras L, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, et al.
Vet Comp Oncol . 2016 May; 15(3):996-1013. PMID: 27146852
Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards...
7.
Iussich S, Maniscalco L, Di Sciuva A, Iotti B, Morello E, Martano M, et al.
Vet Comp Oncol . 2016 Feb; 15(2):462-469. PMID: 26833575
Canine malignant melanoma (CMM) is the most common canine oral tumour, and up to 70-75% of dogs in stage II-III die within 1 year after surgery. The purpose of this...
8.
Sanchez-Cespedes R, Maniscalco L, Iussich S, Martignani E, Guil-Luna S, De Maria R, et al.
Vet J . 2013 Apr; 197(2):474-82. PMID: 23583698
Mammary gland tumours, the most common malignant neoplasm in bitches, often display myoepithelial (ME) cell proliferation. The aim of this study was to isolate, purify, culture and characterise ME cells...
9.
Maniscalco L, Iussich S, Martin de Las Mulas J, Millan Y, Biolatti B, Sasaki N, et al.
Vet J . 2011 Feb; 191(1):65-71. PMID: 21282070
The PI3K/AKT/PTEN pathway is involved in the pathogenesis of several human cancers. This study investigated the biological and prognostic value of PI3K/AKT/PTEN pathway dysregulation in feline mammary tumours. Expression of...
10.
De Maria R, Divari S, Spada F, Oggero C, Mulasso C, Maniscalco L, et al.
Vet Rec . 2010 Aug; 167(8):291-6. PMID: 20729516
This study investigated progesterone receptor (PR) cDNA expression in the testes, prostate and bulbourethral glands of prepubertal calves treated experimentally with high and low doses of 17beta-oestradiol and with testosterone....